Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Projected Compound Annual Growth Rate (CAGR) of the Chronic Spontaneous Urticaria Market from 2025 to 2034, and What Factors Influence It?

There has been significant expansion in the chronic spontaneous urticaria market in the past few years. The market is forecasted to increase from $2.06 billion in 2024 to $2.23 billion in 2025, representing a compound annual growth rate (CAGR) of 8.6%. This growth, during the historical period, is due to the development of enhanced diagnostic instruments, increased awareness among healthcare, patient support groups, and advocates, current research and clinical trials investigating new treatments, and rising health care spending.

In the coming years, the market size of chronic spontaneous urticaria is projected to experience substantial growth, reaching $3.08 billion by 2029 with a compound annual growth rate (CAGR) of 8.4%. This surge during the forecast period is likely due to the escalating numbers of diagnosed cases of CSU, an enlarging patient pool, improvements in healthcare infrastructure, a supportive regulatory context, patient-focused treatment models, and economic development in rising markets. Significant trends for the forecast period encompass technological breakthroughs, progressive biological therapies, tailored medicine, telehealth and digital healthcare, improved diagnosis tools, the application of AI and machine learning, and a rise in drug authorizations and introductions.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Chronic Spontaneous Urticaria Market?

The expected growth in the chronic spontaneous urticaria market is anticipated to be driven by rising alcohol consumption. The surge in alcohol intake can be linked to various elements such as societal expectations, stress, promotional activities, cost-effectiveness, and easy accessibility. Drinking alcohol may intensify chronic spontaneous urticaria symptoms in certain individuals, leading to an uptick in hives and inflammation. As per data from rehabs.UK, a British organization that provides assistance and advice for overcoming addiction, in February 2024, 55% of males reported consuming alcohol on a weekly basis, while the figure stood at 41% for females. Moreover, 8% of males and 5% of females reported nearly daily alcohol consumption. From 2021 to 2022, alcohol-related hospital admissions amounted to 342,795, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the escalating alcohol consumption is fueling the expansion of the chronic spontaneous urticaria market.

Get Your Free Sample of the Global Chronic Spontaneous Urticaria Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Who Are the Leading Players Fueling Growth in the Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are:

• F. Hoffmann-La Roche Ltd.

• Merck & Co. Inc.

• AbbVie Inc.

• Bayer AG

• Sanofi SA

What Are the Emerging Trends Shaping the Future of the Chronic Spontaneous Urticaria Market?

Leading firms in the chronic spontaneous urticaria market are focusing on the development of advanced Briquilimab (JSP191) to improve the efficacy of treatment and reduce the need for frequent doses. Briquilimab (JSP191) is a next-generation monoclonal antibody that specifically targets and eradicates certain immune cells, mainly those targeting CD47, in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a clinical-stage biotech firm based in the US, disclosed its first patient dosage in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is crucial in determining the safety and efficiency of Briquilimab, a next-generation monoclonal antibody targeting CD47, in addressing this recurring skin condition characterized by hives and itching. The study aims to evaluate the ability of Briquilimab to alleviate symptoms and enhance the life quality of those battling CSU.

Get Instant Access to the Global Chronic Spontaneous Urticaria Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Segments of the Chronic Spontaneous Urticaria Market Hold the Most Potential for Future Development?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Which Regions Are Driving Growth in the Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Chronic Spontaneous Urticaria Market?

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body’s immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.

Browse Through More Similar Reports By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Cough Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: